Nexien Biopharma IncOTC Pink - Current Information:NXEN
- LAST PRICE0.0150
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0134/ 100
- Ask / Lots0.0200/ 100
- Open / Previous Close0.0150 / 0.0150
- Day Range
- 52 Week Range
- Volume2,911
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NXEN |
|---|---|---|
| 10:27 ET | 2911 | 0.015 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nexien Biopharma Inc | 1.1M | -5.2x | --- |
Link Reservations Inc | 740.0K | 0.0x | --- |
Cann American Corp | 850.4K | 0.0x | --- |
ITonis Inc | 761.7K | -0.3x | --- |
Lucy Scientific Discovery Inc | 10.6K | 0.0x | --- |
Nunzia Pharmaceutical Corp | 430.0 | 0.0x | --- |
Company Information
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. The Company is utilizing cannabinoids as the active pharmaceutical ingredients to develop synthetic pharmaceuticals in strict accordance with the U.S. FDA pre-clinical and clinical pathways. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
Contact Information
- Headquarters
- 4340 E Kentucky Ave Ste 206GLENDALE, CO, United States 80246-2067
- Phone
- 303-495-7583
- Fax
- 302-645-1280
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.8M |
Nexien Biopharma Inc does not pay a dividend. | |
Beta | 0.69 |
EPS | $0.00 |
Book Value | $-0.01 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
